Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $56.2 million.

  • Myriad Genetics' Cash from Financing Activities rose 191290.32% to $56.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.5 million, marking a year-over-year decrease of 3371.89%. This contributed to the annual value of -$7.4 million for FY2024, which is 10483.98% down from last year.
  • Myriad Genetics' Cash from Financing Activities amounted to $56.2 million in Q3 2025, which was up 191290.32% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Cash from Financing Activities peaked at $121.9 million during Q4 2023, and registered a low of -$74.5 million during Q3 2021.
  • Its 5-year average for Cash from Financing Activities is $3.1 million, with a median of -$2.1 million in 2022.
  • As far as peak fluctuations go, Myriad Genetics' Cash from Financing Activities plummeted by 2435000.0% in 2021, and later surged by 590476.19% in 2023.
  • Over the past 5 years, Myriad Genetics' Cash from Financing Activities (Quarter) stood at -$1.1 million in 2021, then tumbled by 90.91% to -$2.1 million in 2022, then skyrocketed by 5904.76% to $121.9 million in 2023, then tumbled by 98.28% to $2.1 million in 2024, then surged by 2576.19% to $56.2 million in 2025.
  • Its last three reported values are $56.2 million in Q3 2025, $2.6 million for Q2 2025, and $13.6 million during Q1 2025.